HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Apoptosis-inducing high (.)NO concentrations are not sustained either in nascent or in developed cancers.

Abstract
Nitric oxide ((.)NO) induces apoptosis at high concentrations by S-nitrosating proteins such as glyceraldehyde-3-phosphate dehydrogenase. This literature analysis revealed that failure to sustain high (.)NO concentrations is common to all cancers. In cervical, gastric, colorectal, breast, and lung cancer, the cause of this failure is the inadequate expression of inducible nitric oxide synthase (iNOS), resulting from the inhibition of iNOS expression by TGF-beta1 at the mRNA level. In bladder, renal, and prostate cancer, the reason for the insufficient (.)NO levels is the depletion of arginine, resulting from arginase overexpression. Arginase competes with iNOS for arginine, catalyzing its hydrolysis to ornithine and urea. In gliomas and ovarian sarcomas, low (.)NO levels are caused by inhibition of iNOS by N-chlorotaurine, produced by infiltrating neutrophils. Stimulated neutrophils express myeloperoxidase, catalyzing H2O2 oxidation of Cl- to HOCl, which N-chlorinates taurine at its concentration of 19 mM in neutrophils. In squamous cell carcinomas of the skin, ovarian cancers, lymphomas, Hodgkin's disease, and breast cancers, low (.)NO concentrations arise from the inhibition of iNOS by N-bromotaurine, produced by eosinophil-peroxidase-expressing infiltrating eosinophils. Eosinophil peroxidase catalyzes the H2O2 oxidation of Br- to HOBr, which N-brominates taurine to N-bromotaurine at its concentration of 15 mM in eosinophils. In microvascularized tumors, the (.)NO concentration is further depleted; (.)NO is rapidly consumed by red blood cells (RBCs) through S-nitrosation of RBC glutathione and hemoglobin, and by oxidation to nitrate by RBC oxyhemoglobin. Angiogenesis-inhibiting antibodies are currently used to treat cancers; their mode of action is not, as previously thought, reduction of the tumor O2 or nutrient supply. They actually decrease the loss of (.)NO to RBCs.
AuthorsAdam Heller
JournalChemMedChem (ChemMedChem) Vol. 3 Issue 10 Pg. 1493-9 (Oct 2008) ISSN: 1860-7187 [Electronic] Germany
PMID18759245 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Transforming Growth Factor beta1
  • Taurine
  • Nitric Oxide
  • Peroxidase
  • Nitric Oxide Synthase Type II
  • Arginase
Topics
  • Apoptosis
  • Arginase (genetics, metabolism)
  • Erythrocytes (metabolism)
  • Humans
  • Neoplasms (enzymology, etiology, genetics)
  • Neutrophils (metabolism)
  • Nitric Oxide (chemistry, metabolism)
  • Nitric Oxide Synthase Type II (genetics, metabolism)
  • Oxidation-Reduction
  • Peroxidase (genetics, metabolism)
  • Taurine (metabolism)
  • Transforming Growth Factor beta1 (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: